Advaxis Company Profile (NASDAQ:ADXS)

About Advaxis (NASDAQ:ADXS)

Advaxis logoAdvaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADXS
  • CUSIP: N/A
  • Web: www.advaxis.com
Capitalization:
  • Market Cap: $161.39 million
  • Outstanding Shares: 41,065,000
Average Prices:
  • 50 Day Moving Avg: $4.88
  • 200 Day Moving Avg: $6.67
  • 52 Week Range: $3.76 - $10.88
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.78
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $14.01 million
  • Price / Sales: 11.11
  • Book Value: $1.81 per share
  • Price / Book: 2.09
Profitability:
  • EBITDA: ($93,950,000.00)
  • Net Margins: -655.66%
  • Return on Equity: -93.54%
  • Return on Assets: -64.49%
Debt:
  • Current Ratio: 4.60%
  • Quick Ratio: 4.60%
Misc:
  • Average Volume: 766,965 shs.
  • Beta: 2.17
  • Short Ratio: 21.4
 

Frequently Asked Questions for Advaxis (NASDAQ:ADXS)

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) posted its earnings results on Monday, September, 11th. The company reported ($0.80) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.27. The firm had revenue of $3.05 million for the quarter, compared to analyst estimates of $3.43 million. Advaxis had a negative return on equity of 93.54% and a negative net margin of 655.66%. View Advaxis' Earnings History.

When will Advaxis make its next earnings announcement?

Advaxis is scheduled to release their next quarterly earnings announcement on Tuesday, January, 16th 2018. View Earnings Estimates for Advaxis.

Where is Advaxis' stock going? Where will Advaxis' stock price be in 2017?

2 brokerages have issued 1-year target prices for Advaxis' stock. Their predictions range from $19.00 to $23.00. On average, they expect Advaxis' share price to reach $21.00 in the next year. View Analyst Ratings for Advaxis.

Who are some of Advaxis' key competitors?

Who are Advaxis' key executives?

Advaxis' management team includes the folowing people:

  • David Sidransky M.D., Independent chairman of the Board of Director
  • Anthony Lombardo, Interim Chief Executive Officer
  • Sara M. Bonstein, Chief Financial Officer, Executive Vice President
  • Robert G. Petit Ph.D., Executive Vice President, Chief Scientific Officer
  • James P. Patton M.D., Non-Executive Independent Vice Chairman of the Board
  • Gregory T. Mayes III, Director
  • Roni A. Appel, Independent Director
  • Richard J. Berman J.D., Independent Director
  • Samir N. Khleif, Independent Director

Who owns Advaxis stock?

Advaxis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (11.45%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Daniel O'connor, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.

How do I buy Advaxis stock?

Shares of Advaxis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Advaxis' stock price today?

One share of Advaxis stock can currently be purchased for approximately $3.79.


MarketBeat Community Rating for Advaxis (NASDAQ ADXS)
Community Ranking:  4.0 out of 5 (star star star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  234
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Advaxis (NASDAQ:ADXS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $21.00 (454.09% upside)
Consensus Price Target History for Advaxis (NASDAQ:ADXS)
Price Target History for Advaxis (NASDAQ:ADXS)
Analysts' Ratings History for Advaxis (NASDAQ:ADXS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Cantor FitzgeraldReiterated RatingBuy$19.00HighView Rating Details
9/15/2017HC WainwrightReiterated RatingBuy$23.00LowView Rating Details
9/9/2016Jefferies Group LLCReiterated RatingBuy$24.00N/AView Rating Details
8/3/2016Barclays PLCBoost Price TargetOverweight$15.00 -> $20.00N/AView Rating Details
7/7/2016FBR & CoReiterated RatingOutperform$34.00N/AView Rating Details
12/17/2015Janney Montgomery ScottReiterated RatingBuy$22.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Advaxis (NASDAQ:ADXS)
Earnings by Quarter for Advaxis (NASDAQ:ADXS)
Earnings History by Quarter for Advaxis (NASDAQ ADXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/16/2018($0.55)N/AView Earnings Details
9/11/2017Q3($0.53)($0.80)$3.43 million$3.05 millionViewN/AView Earnings Details
3/10/2017Q1 2017($0.52)($0.43)$2.15 million$3.79 millionViewN/AView Earnings Details
6/8/2016Q2 2016($0.54)($0.45)$0.13 millionViewN/AView Earnings Details
3/13/2015Q1 2015($0.31)($0.33)ViewN/AView Earnings Details
6/9/2014Q3 2014($0.25)($0.30)$1.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Advaxis (NASDAQ:ADXS)
2017 EPS Consensus Estimate: ($2.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.51)($0.51)($0.51)
Q2 20171($0.54)($0.54)($0.54)
Q3 20171($0.61)($0.61)($0.61)
Q4 20171($0.64)($0.64)($0.64)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Advaxis (NASDAQ:ADXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Advaxis (NASDAQ:ADXS)
Insider Ownership Percentage: 7.21%
Institutional Ownership Percentage: 48.06%
Insider Trades by Quarter for Advaxis (NASDAQ:ADXS)
Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)
Insider Trades by Quarter for Advaxis (NASDAQ:ADXS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/11/2017Adage Capital Partners Gp, L.LMajor ShareholderSell600,000$4.30$2,580,000.00View SEC Filing  
9/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,239,323$4.42$5,477,807.66View SEC Filing  
3/31/2017Robert PetitInsiderSell2,454$8.24$20,220.96View SEC Filing  
12/30/2016Sara BonsteinCFOSell5,520$7.37$40,682.40View SEC Filing  
12/20/2016Thomas J MckearnDirectorSell12,316$8.08$99,513.28View SEC Filing  
11/2/2016Daniel O'connorCEOSell8,240$8.32$68,556.80View SEC Filing  
11/2/2016Robert PetitInsiderSell2,797$8.32$23,271.04View SEC Filing  
10/25/2016Gregory T MayesInsiderSell19,162$8.23$157,703.26View SEC Filing  
8/9/2016David SidranskyDirectorSell22,808$15.01$342,348.08View SEC Filing  
8/8/2016Richard J BermanDirectorSell18,000$15.21$273,780.00View SEC Filing  
5/13/2016Thomas J MckearnDirectorSell4,100$7.45$30,545.00View SEC Filing  
5/2/2016Daniel O'connorCEOSell8,237$7.51$61,859.87View SEC Filing  
5/2/2016Robert PetitInsiderSell2,785$7.51$20,915.35View SEC Filing  
3/31/2016Robert PetitInsiderSell3,325$9.13$30,357.25View SEC Filing  
3/16/2016Thomas J MckearnDirectorSell14,000$8.25$115,500.00View SEC Filing  
2/24/2016Sara BonsteinCFOSell15,037$5.58$83,906.46View SEC Filing  
1/29/2016Daniel O'connorCEOSell8,818$6.88$60,667.84View SEC Filing  
1/29/2016Robert PetitinsiderSell3,099$6.88$21,321.12View SEC Filing  
10/26/2015Gregory T MayesCOOSell19,231$11.63$223,656.53View SEC Filing  
10/20/2015David J MauroInsiderSell24,586$10.08$247,826.88View SEC Filing  
8/24/2015Adage Capital Partners Gp LlcMajor ShareholderBuy300,000$14.15$4,245,000.00View SEC Filing  
4/30/2015Adage Capital Partners Gp LlcMajor ShareholderBuy500,000$19.00$9,500,000.00View SEC Filing  
2/18/2015Adage Capital Partners Gp LlcMajor ShareholderBuy684,762$7.50$5,135,715.00View SEC Filing  
5/9/2014Richard J BermanDirectorSell14,530$2.63$38,213.90View SEC Filing  
3/31/2014Daniel O'connorCEOBuy3,333$3.00$9,999.00View SEC Filing  
10/24/2013Daniel O'connorCEOBuy13,500$4.00$54,000.00View SEC Filing  
10/24/2013Mark J RosenblumCFOBuy12,000$4.00$48,000.00View SEC Filing  
10/24/2013Robert PetitInsiderBuy12,800$4.00$51,200.00View SEC Filing  
10/24/2013Roni AppelDirectorBuy12,500$4.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Advaxis (NASDAQ:ADXS)
Latest Headlines for Advaxis (NASDAQ:ADXS)
Source:
DateHeadline
americanbankingnews.com logoAdvaxis, Inc. (ADXS) Major Shareholder Adage Capital Partners Gp, L.L Sells 600,000 Shares
www.americanbankingnews.com - October 12 at 4:12 PM
thestreet.com logoShort Interest Decreases By 15.8% For ADXS
www.thestreet.com - October 11 at 9:27 PM
americanbankingnews.com logoHead-To-Head Review: Advaxis (ADXS) vs. Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - October 5 at 4:30 AM
finance.yahoo.com logoEarnings Review and Free Research Report: Advaxis Reported its Q3 FY17 Results
finance.yahoo.com - October 3 at 3:18 PM
finance.yahoo.com logoInsiders Roundup: Twitter, McKesson Make Biggest Trades
finance.yahoo.com - September 30 at 1:43 PM
americanbankingnews.com logoAdvaxis, Inc. (ADXS) Major Shareholder Adage Capital Partners Gp, L.L Sells 1,239,323 Shares
www.americanbankingnews.com - September 26 at 7:24 PM
americanbankingnews.com logoAdvaxis, Inc. (ADXS) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - September 25 at 4:06 PM
finance.yahoo.com logoAdvaxis to Webcast Company Overview at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 23 at 9:33 AM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: September 20, 2017 - Seeking Alpha
seekingalpha.com - September 20 at 3:26 PM
finance.yahoo.com logoTwo Abstracts Featuring Advaxis’ Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer (SITC) Meeting
finance.yahoo.com - September 19 at 3:33 PM
finance.yahoo.com logoCorporate News Blog - EMA Grants Positive CHMP Opinion to Tesaro’s Ovarian Cancer Drug
finance.yahoo.com - September 18 at 3:57 PM
finance.yahoo.com logoAdvaxis to Present at Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 18 at 3:57 PM
americanbankingnews.com logoCantor Fitzgerald Equities Analysts Decrease Earnings Estimates for Advaxis, Inc. (ADXS)
www.americanbankingnews.com - September 18 at 3:42 AM
americanbankingnews.com logoAdvaxis, Inc. (ADXS) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - September 15 at 4:52 PM
thestreet.com logoRelative Strength Alert For Advaxis
www.thestreet.com - September 13 at 4:18 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Advaxis and Heat Biologics
finance.yahoo.com - September 13 at 4:18 PM
seekingalpha.com logoWhere Do The Chips Fall For Advaxis Going Into Q4 2017? - Seeking Alpha
seekingalpha.com - September 12 at 8:45 PM
finance.yahoo.com logoHere's Why Advaxis, Inc. Stock Is Getting Pummeled Today
finance.yahoo.com - September 12 at 3:45 PM
feeds.benzinga.com logo10 Biggest Mid-Day Losers For Thursday
feeds.benzinga.com - September 12 at 2:28 PM
fool.com logoHere's Why Advaxis, Inc. Stock Is Getting Pummeled Today
www.fool.com - September 12 at 1:57 PM
americanbankingnews.com logoAdvaxis, Inc. (ADXS) Announces Quarterly Earnings Results
www.americanbankingnews.com - September 12 at 9:22 AM
finance.yahoo.com logoAdvaxis reports 3Q loss
finance.yahoo.com - September 11 at 9:10 PM
businesswire.com logoAdvaxis Reports Business Update and Third Quarter 2017 Results - Business Wire (press release)
www.businesswire.com - September 11 at 4:07 PM
finance.yahoo.com logoAdvaxis Reports Business Update and Third Quarter 2017 Results
finance.yahoo.com - September 11 at 4:06 PM
finance.yahoo.com logoWhat Does Advaxis Inc’s (ADXS) Share Price Indicate?
finance.yahoo.com - September 8 at 8:56 PM
businesswire.com logoAdvaxis to Present at Third CRI-CIMT-EATI-AACR International ... - Business Wire (press release)
www.businesswire.com - August 2 at 8:31 PM
finance.yahoo.com logoAdvaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
finance.yahoo.com - August 2 at 3:27 PM
finance.yahoo.com logoAdvaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders
finance.yahoo.com - July 13 at 4:09 PM
streetinsider.com logoAdvaxis (ADXS) CEO, President and Board Member, Daniel O'Connor to Resign; Anthony Lombardo to Assume Interim CEO Role
www.streetinsider.com - July 8 at 3:16 PM
americanbankingnews.com logoCantor Fitzgerald Reiterates "$19.00" Price Target for Advaxis, Inc. (NASDAQ:ADXS)
www.americanbankingnews.com - July 7 at 6:56 PM
benzinga.com logoStocks To Watch For July 7, 2017 - Benzinga
www.benzinga.com - July 7 at 5:14 PM
streetinsider.com logoPre-Open Movers 07/07: (DGLY) (SNCR) (CLB) Higher; (CHKE) (RSYS) (ADXS) Lower (more...) - StreetInsider.com
www.streetinsider.com - July 7 at 5:14 PM
streetinsider.com logoAfter-Hours Movers 07/06: (SNCR) (CLB) (DGSE) Higher; (CHKE) (RSYS) (ADXS) Lower (more...) - StreetInsider.com
www.streetinsider.com - July 7 at 2:58 AM
streetinsider.com logoAdvaxis (ADXS) CEO, President and Board Member, Daniel O'Connor to Resign; Anthony Lombardo to Assume Interim ... - StreetInsider.com
www.streetinsider.com - July 7 at 2:58 AM
finance.yahoo.com logoAdvaxis Announces Change in Leadership
finance.yahoo.com - July 6 at 4:52 PM
finance.yahoo.com logoAdvaxis CEO Daniel O'Connor resigns
finance.yahoo.com - July 6 at 4:52 PM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: June 28, 2017
seekingalpha.com - June 28 at 3:47 PM
businesswire.com logoAdvaxis' Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 - Business Wire (press release)
www.businesswire.com - June 26 at 3:49 PM
investopedia.com logoAdvaxis Breaks Down From Key Support Levels (ADXS)
www.investopedia.com - June 17 at 1:48 AM
seekingalpha.com logoAdvaxis At A New 52-Week Low: Panic Or Payload? - Seeking Alpha
seekingalpha.com - June 16 at 3:47 PM
businesswire.com logoAdvaxis to Be Featured on Worldwide Business with kathy ireland ®
www.businesswire.com - June 15 at 1:25 AM
streetinsider.com logoAdvaxis (ADXS) Offers Details on Registrational Trials, EU Regulatory and Commercial Plans - StreetInsider.com
www.streetinsider.com - June 14 at 3:22 PM
prnewswire.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Advaxis, Inc. for Potential Breaches Of Fiduciary ... - PR Newswire (press release)
www.prnewswire.com - June 5 at 1:36 PM
prnewswire.com logoSynthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis ... - PR Newswire (press release)
www.prnewswire.com - June 1 at 3:28 PM
seekingalpha.com logoAdvaxis teams up with Bristol-Myers on cervical cancer combo - Seeking Alpha
seekingalpha.com - May 31 at 3:20 PM
seekingalpha.com logoCreating Index Tracking Portfolios With Beta Convexity
seekingalpha.com - May 31 at 11:13 AM
businesswire.com logoAdvaxis and Bristol-Myers Squibb Announce Clinical Collaboration ... - Business Wire (press release)
www.businesswire.com - May 30 at 3:30 PM
seekingalpha.com logo3 Things In Biotech You Should Learn Today: May 18, 2017
seekingalpha.com - May 18 at 12:25 PM
businesswire.com logoAdvaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac - Business Wire (press release)
www.businesswire.com - May 15 at 3:22 PM
thestreet.com logoCommit To Buy Advaxis At $7.50, Earn 16.4% Annualized Using Options - TheStreet.com
www.thestreet.com - April 27 at 8:44 PM

Social

Chart

Advaxis (ADXS) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.